BEAD BIOPHARMA LIMITED

Active Edinburgh

Research and experimental development on biotechnology

2 employees website.com
Research and experimental development on biotechnology
B

BEAD BIOPHARMA LIMITED

Research and experimental development on biotechnology

Founded 22 Mar 2023 Active Edinburgh, Scotland 2 employees website.com
Research and experimental development on biotechnology
Accounts Submitted 10 Nov 2025 Next due 31 Dec 2026 8 months remaining
Confirmation Submitted 23 Mar 2026 Next due 4 Apr 2027 11 months remaining
Net assets £483K £524K 2024 year on year
Total assets £536K £531K 2024 year on year
Total Liabilities £52K £7K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

6 Logie Mill Edinburgh EH7 4HG Scotland

Full company profile for BEAD BIOPHARMA LIMITED (SC763273), an active company based in Edinburgh, Scotland. Incorporated 22 Mar 2023. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2023–2024)

Cash in Bank

£459.56k

Net Assets

£483.40k

Increased by £523.80k (+1296%)

Total Liabilities

£52.39k

Increased by £7.07k (+16%)

Turnover

N/A

Employees

2

Debt Ratio

10%

Decreased by 912 (-99%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

2 Allotments 146,995 Shares £2.51m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
24 Oct 202561,280£1.61m£26.34
2 Apr 202485,715£900k£10.5

Officers

Officers

1 active 2 resigned
Status
Sun, MichaelDirectorAmericanUnited States542 Apr 2024Active

Shareholders

Shareholders (56)

David Moody
58.1%
166,000
The Quaternary Group
3.9%
11,010

Persons with Significant Control

Persons with Significant Control (3)

3 Active

David John Moody

British

Active
Notified 22 Mar 2023
Residence Scotland
DOB November 1959
Nature of Control
  • Ownership Of Shares 50 To 75 Percent,voting Rights 50 To 75 Percent,right To Appoint And Remove Directors

Dr David John Moody

British

Active
Notified 22 Mar 2023
Residence Scotland
DOB November 1959
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

Dr David John Moody

British

Active
Notified 22 Mar 2023
Residence Scotland
DOB November 1959
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
7 Apr 2026AddressChange Registered Office Address Company With Date Old Address New Address
23 Mar 2026Confirmation StatementConfirmation statement made on 21 Mar 2026 with updates
5 Dec 2025OfficersAppointment of Dr Daniel Matthew Ozanne as director on 1 Dec 2025
10 Nov 2025AccountsAnnual accounts made up to 31 Mar 2025
27 Oct 2025CapitalAllotment of shares (GBP 34.6995) on 24 Oct 2025
7 Apr 2026 Address

Change Registered Office Address Company With Date Old Address New Address

23 Mar 2026 Confirmation Statement

Confirmation statement made on 21 Mar 2026 with updates

5 Dec 2025 Officers

Appointment of Dr Daniel Matthew Ozanne as director on 1 Dec 2025

10 Nov 2025 Accounts

Annual accounts made up to 31 Mar 2025

27 Oct 2025 Capital

Allotment of shares (GBP 34.6995) on 24 Oct 2025

Recent Activity

Latest Activity

Change Registered Office Address Company With Date Old Address New Address

3 weeks ago on 7 Apr 2026

Confirmation statement made on 21 Mar 2026 with updates

1 months ago on 23 Mar 2026

Appointment of Dr Daniel Matthew Ozanne as director on 1 Dec 2025

4 months ago on 5 Dec 2025

Annual accounts made up to 31 Mar 2025

5 months ago on 10 Nov 2025

Allotment of shares (GBP 34.6995) on 24 Oct 2025

6 months ago on 27 Oct 2025